Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/02—Linear peptides containing at least one abnormal peptide link
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
  • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Definitions

• the invention relates to chemically defined polymeric carriers that provide advantageous properties for in vivo imaging and therapy.
• the polymeric carriers consist of ⁇ -amino acids that contain side chains covalently joined to (i) diagnostic and therapeutic molecules and (ii) chelating agents capable of binding diagnostic or therapeutic radionuclides.
• Monoclonal antibodies have been developed that localize in cancerous tissue, due to their high specificity and affinity for antigens on tumor cell surfaces. This development has increased the prospect of clinical applications, if such antibodies can be linked to diagnostic and therapeutic agents. The high specificity of the antibodies makes them desirable candidates as targeting molecules for delivering a diagnostic or therapeutic agent to a cancer site.
• Regulatory agencies require that all substances subject to their approval must include information that clearly identifies the structure of the substance, which is to be introduced into the body. What is needed is an approach that derivatizes a targeting molecule, such as an antibody, at a minimum number of sites to carry larger amounts of diagnostic and therapeutic agents. Also needed, is an approach that can determine the nature of the chelating agent linkage to the antibody and the number of chelating agents linked to the antibody.
• the present invention provides a chemically defined polymeric carrier. It comprises a series of ⁇ -amino acids, in any combination, containing side chains to which diagnostic/therapeutic and chelating agents can be covalently joined through cleavable linkers.
• the agents can be covalently joined to the side chains through cleavable linkers either directly or covalently joined to the side chains through cleavable linkers after chemical modification of the side chains. Hydrazone, disulfide, and ester linkages, in any combination, can be present in the polymeric carrier between the side chains of the ⁇ -amino acids and the agents.
• the selection of a particular covalent linkage between the side chain and the agent in the polymeric carrier is determined by the functional group in the ⁇ -amino acid side chain and the reactive functional group in the agent.
• the ⁇ -amino acids with side chains to which agents do not covalently join can function as spacers, to minimize interaction between the bulky molecules attached to the polymeric carrier.
• those ⁇ -amino acids with charged or hydrophilic side chains to which agents do not covalently join can provide increased solubility to the polymeric carrier.
• N-terminal protecting groups which are optional for the polymeric carrier include all the standard amine protecting groups.
• C-terminal conjugation groups which are optional for attachment of the polymeric carrier to the targeting molecule include all conjugation groups known in the art.
• a spacer group is present in the polymeric carrier between the ⁇ -amino acids and the conjugation group. The spacer group presents any steric hindrance to the attachment by any agent appended from the C-terminal end of the carrier. These spacer groups are terminal aminoacids, such as 7-aminobutyric acid (Aba).
• the spacer group e.g., Aba through its carboxyl group, can attach the polymeric carrier to the targeting molecule.
• the peptides that constitute the polymeric carrier are prepared from ⁇ -amino acids by conventional solution methods or by solid-phase peptide synthesis. These peptides have been modified to carry derivatized diagnostic/ therapeutic agents, and chelating agents that bind to diagnostic and therapeutic radionuclides. These agents can be released either at the target site or after internalization by the cell. Many advantages arise from the present invention.
• the polymeric carrier can carry a maximum number of agents while derivatizing a targeting molecule at a minimum number of sites. Thus the biological activity of the targeting molecule is maintained at a high level, even though it is attached to multiple agents. For example, the fewer the linkages in an antibody, the higher is its specificity.
• the rate at which agents can be released from the polymeric carrier attached to the targeting molecule is controlled by manipulating the nature of the covalent linkages in the polymeric carrier. For example, by adjusting the stability of the covalent linkages or by using different types of covalent linkages on a polymeric carrier, agents--are released at a mixed rate. This is particularly important when the disease requires use of long term diagnostics or therapeutics.
• agents which may be the same or different, are attached to the polymeric carrier. Not only can the same agents be released at a mixed rate, but different agents can be released at a mixed rate in the same target site.
• the polymeric carrier with its covalently linked agents, is a relatively small molecule compared to the targeting molecule. Therefore, conventional detection techniques can predetermine the exact nature of the agent linkages to the targeting molecule before the polymeric carrier is attached to it. In addition, radiolabeling techniques can determine the precise number of polymeric carriers linked to the targeting molecule.
• Figure 1 is a flow chart representing the general procedure for synthesis of a polymeric carrier with attached agents and the conjugation of the polymeric carrier to an antibody.
• Figure 2 is a flow chart representing a procedure for the synthesis of a polymeric carrier with attached therapeutic agents and the conjugation of the polymeric carrier to an antibody.
• Figure 3 illustrates the removal of protecting groups from amino acid side chains of a polymeric carrier.
• Figures 4 and 6 are flow charts representing procedures for the synthesis of polymeric carriers with attached chelating agents and the conjugation of the polymeric carriers to antibodies.
• Figure 5 is a flow chart representing a procedure for the synthesis of a chelating agent.
• the present invention relates to a chemically defined polymeric carrier that increases the loading of diagnostic/therapeutic and chelating agents to targeting molecules.
• the polymeric carrier comprises a series of from 2 to about 18 ⁇ -amino acids in any combination that include side chains which can covalently join through cleavable linkers to agents.
• the number of agents covalently joined through cleavable linkers to the polymeric carrier can be from 2 to about 18. This number is determined by the number of ⁇ -amino acid side chains in the polymeric carrier available for covalent bonding through cleavable linkers to the agents.
• polymeric carrier denotes a peptide carrier.
• Those ⁇ -amino acids whose side chains are not covalently joined to agents can function as spacers for the polymeric carrier. These spacers reduce any non-bonded interactions between agents attached to modified ⁇ -amino acids.
• those ⁇ -amino acids with charged or hydrophilic side chains not covalently joined to agents can impart increased solubility to the polymeric carrier.
• the polymeric carrier includes optionally a protecting group at its N-terminal end and optionally a conjugation group at its C-terminal end.
• the conjugation group enables the polymeric carrier to attach itself to a targeting molecule.
• a spacer group is placed between the ⁇ -amino acids and the conjugation group to aid in the attachment of the polymeric carrier to the targeting molecule.
• the spacer group prevents any steric hindrance to the attachment by any agent appended from the C-terminal end of the carrier.
• the spacer group a terminal amino acid, may attach the polymeric carrier to the targeting molecule without the presence of the conjugation group.
• the ⁇ -amino acids having side chains that enhance water solubility include those with charged side chains (lysine, arginine, histidine, cysteine, aspartic acid, glutamic acid, tyrosine, tyrosine-O-SO 3 -) and those with hydrophilic side chains (serine, threonine, asparagine, glutamine).
• Standard amine protecting groups can be used for the N-terminal protecting group of the polymeric carrier.
• Preferred embodiments of the invention comprise acetyl, proprionyl, phenylacylsulfonyl, substituted phenyl- acylsulfonyl, and other hydrophilic protecting groups.
• a conjugation group is a chemically reactive functional group that will react with a targeting molecule to bind the polymeric carrier thereto.
• the targeting molecule is a protein
• the conjugation group is reactive under conditions that do not denature or otherwise adversely affect the protein. Therefore, the conjugation group is sufficiently reactive with a functional group on a protein so that the reaction can be conducted in a substantially aqueous solution and does not have to be forced, e.g., by heating to high temperatures, which may denature the protein.
• suitable conjugation groups include but are not limited to active esters, isothiocyanates, amines, hydrazines, maleimides or other Michael-type acceptors, thiols, and activated halides.
• the preferred active esters are N-hydroxysuccinimidyl ester, sulfosuccinimidyl ester, thiophenyl ester, 2,3,5,6-tetrafluorophenyl ester, and 2,3,5,6-tetrafluorothiophenyl ester.
• the latter three preferred active esters may comprise a group that enhances water solubility, at the para (i.e., 4) or the ortho position on the phenyl ring. Examples of such groups are CO 2 H, SO 3 -, PO 3 2- , OPO 3 2 -, OSO 3 -, N + R 3 wherein each R represents H or an alkyl group, and O(CH 2 CH 2 O) n CH 3 groups.
• Terminal amino acids used as spacer groups in the invent ion include aminocaproic acid, aminopentanoic acid, 7-aminobutyric acid, ⁇ -alanine, glycine, and the like.
• ⁇ -amino acids in the polymeric carrier are from 2 to about 18 units;
• PG is an N-terminal protecting group
• SG is a spacer group that by preventing steric hindrance by agents appended from the C- terminal end of the carrier promotes efficient attachment of the polymeric carrier to a targeting molecule
• CG is a conjugation group useful for the attachment of the polymeric carrier to a targeting molecule
• AGENT is from 2 to about 18 units of a diagnostic or therapeutic agent, or a chelating agent capable of binding diagnostic or therapeutic radionuclides in the polymeric carrier;
• R is H, CH 3 , phenyl, or phenyl substituted with electron-donating and/or electron-withdrawing groups
• q is 0 or 1
• r is 0 or 1
• s is 0 or 1.
• Hydrazone formation is an effective method of attaching certain therapeutic agents to monoclonal antibodies (King et al., Biochemistry, Vol. 25:5774, 1986). Recent work in the area of therapeutic immunoconjugates addressed the hydrazone functionality as a potentially cleavable linker between a chemotherapeutic agent and a monoclonal antibody. Laguzza et al., (J. Med. Chem., Vol. 32:548, 1989) demonstrated that a vinca alkaloid can be conjugated to an antibody via a hydrazone linkage and that pH dependency of the drug could be studied.
• the hydrazone linkage approach was based on the premise that a conjugate formed via a serum stable, yet acid-labile hydrazone linker would serve the purpose of delivering the drug conjugate to the tumor site and then slowly release upon exposure to the tumor's acidic environment (Tannock et al., Cancer Research. Vol. 49:4373, 1989). This conditional requirement necessitated the screening of several small molecule hydrazones to evaluate their stability in human serum and acetate buffer at pH 5.6.
• the design of the polymeric carrier system with a hydrazone linkage incorporates the observed results of a small molecule study.
• Peptides of known amino acid sequences are constructed to carry primary or secondary hydroxyl groups (the chain may carry more than one hydroxy amino acid (primary or secondary), which can be oxidized to the carbonyl compound.
• the results of the small molecule study indicate that hy drazones from aromatic aldehydes may be too stable to be useful. Hydrazones derived from aliphatic ketones have a serum half-life of 15-20 hours (generated in the peptides from threonine and other aminoacids containing secondary -OH groups).
• Hydrazones derived from aliphatic aldehydes (generated in the peptides from serine, homoserine and other amino acids containing primary -OH groups) have a serum half-life of 50-60 hours.
• Hydrazones derived from aromatic ketones (generated in the peptides from phenylserine and substituted phenylserines)) have a serum half-life of 130 hours.
• ⁇ -amino acids in the polymeric carrier are from 2 to about 18 units;
• PG is an N-terminal protecting group
• SG is a spacer group that by preventing steric hindrance by agents appended from the C- terminal end of the carrier promotes efficient attachment of the polymeric carrier to a targeting molecule
• CG is a conjugation group useful for the attachment of the polymeric carrier to a targeting molecule
• AGENT is from 2 to about 18 units of a diagnostic or therapeutic agent, or a chelating agent capable of binding diagnostic or therapeutic radionuclides in the polymeric carrier;
• R is H or CH 3 ;
• R' is H or CH 3 ;
• q 1 or 2;
• r is 0 or 1
• s is 0 or 1.
• Agents containing hydroxyl groups react with aspartic and glutamic acid side chains to form polymeric carriers with ester linkages having the following formula:
• PG is an N-terminal protecting group
• SG is a spacer group that by preventing steric hindrance by agents appended from the C- terminal end of the carrier promotes efficient attachment of the polymeric carrier to a targeting molecule
• CG is a conjugation group useful for attachment of the polymeric carrier to a targeting molecule
• AGENT is from 2 to about 18 units of a diagnostic or therapeutic agent, or a chelating agent capable of binding diagnostic the or therapeutic radionuclides in the polymeric carrier; q is 0 or 1;
• r is 0 or 1
• s is 0 or 1.
• EOE refers to an ethoxy ethyl protecting group.
• COOTFP refers to 2,3,5,6-tetrafluorophenyl ester.
• the above chelate is an N 3 S derivative, and N 2 S 2 derivatives follow a similar procedure. Between the chelate and the antibody is a carbon chain attached to the ⁇ -amino group of the antibody. After metabolism takes place in various organs, the major metabolite D is retained in the gut and kidney and is not excreted, according to the following:
• the resulting polymeric carrier can carry more than one radionuclide metal/per attachment to the antibody or fragment and offers the advantage of a metabolite that can be removed via the renal system instead of being retained in the gut.
• Compound H belongs to N 3 S type chelates and J and K belong to the N 2 S 2 chelate system.
• the groups THP (tetrahydropyranyl) and Acm (acetamidomethyl) are used as sulfur protecting groups.
• the targeting molecule is any molecule that will serve to deliver the polymeric carrier with attached diagnostic/therapeutic or chelating agents to a desired target site (e.g., target cells) in vitro or in vivo. Examples of targeting molecules include, but are not limited to, steroids, cholesterol, lymphokines, and those drugs and proteins that bind to a desired target site.
• the targeting molecule may be a targeting protein, which is capable of binding to a desired target site.
• protein as used herein includes proteins, polypeptides, and fragments thereof.
• the targeting protein may bind to a receptor, substrate, antigenic determinant, or other binding site on a target cell or other target site.
• the targeting protein serves to deliver the agent attached thereto by polymeric carrier to a desired target site in vivo.
• targeting proteins include, but are not limited to, antibodies and antibody fragments, hormones, fibrinolytic enzymes, and biologic response modifiers.
• other molecules that localize in a desired target site in vivo although not strictly proteins are included within the definition of the term "targeting proteins” as used herein.
• proteins may be modified, e.g., to produce variants and fragments thereof, as long as the desired biological property (i.e., the ability to bind to the target site) is retained.
• the proteins may be modified by using various genetic engineering or protein engineering techniques.
• antibodies most preferably monoclonal antibodies.
• a number of monoclonal antibodies that bind to a specific type of cell have been developed including monoclonal antibodies specific for tumor-associated antigens in humans.
• monoclonal antibodies that may be used are anti-TAC, or other interleukin-2 receptor antibodies;
• the antibody employed in the present invention may be an intact (whole) molecule, a fragment thereof, or a functional equivalent thereof.
• antibody fragments are F(ab') 2 , -Fab', Fab, and F v fragments, which may be produced by conventional methods or by genetic or protein engineering.
• Proteins contain a variety of functional groups; e.g., carboxylic acid (COOH) or free amine (-NH 2 ) groups, which are available for reaction with a suitable protein conjugation group on a polymeric carrier to bind the polymeric carrier to the targeting protein.
• a suitable protein conjugation group on a polymeric carrier for example, an active ester on the polymeric carrier reacts with epsilon amine groups on lysine residues of proteins to form amide bonds.
• a targeting molecule and/or a polymeric carrier may be derivatized to expose or attach additional reactive functional groups. The derivatization may involve attachment of any of a number of linker molecules such as those available from Pierce Chemical Company, Rockford, Illinois.
• the derivatization may involve chemical treatment of the protein (which may be an antibody). Procedures for generation of free sulfhydryl groups on antibodies or antibody fragments are also known. (See U.S Patent No. 4,659,839). Maleimide conjugation groups on polymeric carriers are reactive with the sulfhydryl (thiol) groups.
• derivatization may involve chemical treatment of the carbohydrate; e.g., glycol cleavage of the sugar moiety of a glycoprotein antibody with periodate to generate free aldehyde groups.
• the free aldehyde groups on the antibody may be reacted with free amine or hydrazine conjugation groups on polymeric carriers.
• therapeutic agents e.g., a drug, therapeutic radionuclide or toxin
• the chemically defined polymeric carrier e.g., a drug, therapeutic radionuclide or toxin
• multiple therapeutic agents which may be the same or different are attached to the polymeric carrier.
• Exemplary therapeutic agents include toxins and drugs.
• preferred toxins include holotoxins, such as abrin, ricin, modecin, Pseudomonas exotoxin A; Diphtheria toxin, pertussis toxin and Shiga toxin; and A chain or "A chain-like" molecules, such as ricin A, abrin A chain, modeccin A chain, the enzymatic portion of pertussis toxin, the enzymatic portion of Shiga toxin, gelonin, pokeweed antiviral protein, saporin, barley toxin, and snake venom peptides.
• Exemplary drugs include daunomycin, adriamycin, vinblastine, doxorubicin, bleomycin, methotrexate, 5-fluorouracil, 6-thioguanine, cytarabine, cyclophosphamide, and similar conventional chemotherapeutics (for example, see Cancer: Principles and Practices of Oncology, 2d ed., V.T. DeVita, Jr., S. Hellman, S.A. Rosenberg, J.B. Lippincott Co., Philadelphia, PA, 1985, Chapter 14).
• Yet other preferred drugs that can be used with the present invention belong to the tricothecene family, with Roridin A particularly preferred.
• radiolabeled molecules are attached to the chemically defined polymeric carrier.
• a multiple number of radiolabeled molecules are attached to the polymeric carrier.
• Radionuclide metal chelates are one type of radiolabeled molecule that may be employed. Many chelating compounds of various structures, as well as methods for the synthesis and radiolabeling thereof to produce radionuclide metal chelates, are known. Chelating compounds comprising various combinations of sulfur, nitrogen, oxygen, and phosphorous donor atoms may be used, for example. The chelating compound may, for example, comprise a total of from four to six donor atoms selected from nitrogen and sulfur atoms. During the radiolabeling procedure, bonds form between the donor atoms and the radionuclide metal, thereby producing a radionuclide metal chelate. Chelating compound (s) may be incorporated into the polymeric carrier during the synthesis procedure.
• the chelating compound (s) may be synthesized separately and subsequently attached to the polymeric carrier.
• One type of chelating compound that may be employed comprises two nitrogen and two sulfur donor atoms and thus may be designated an "N 2 S 2 " chelating compound.
• Suitable N 2 S 2 chelating compounds are described in U.S. Patent number 4,897,255, entitled “Metal Radionuclide Labeled Proteins for Diagnosis and Therapy", which is hereby incorporated by reference in its entirety.
• One example of 20 an N 2 S 2 chelating compound is as follows:
• Any suitable conventional sulfur protecting group (s) may be attached to the sulfur donor atoms of the compounds of the present invention.
• the protecting groups should be removable, either prior to or during the radiolabeling reaction.
• the preferred sulfur protecting groups are Acm and hemithioacetal protecting groups (EOE, THP), which are displaceable from the chelating compound during the radiolabeling reaction.
• the N 2 S 2 chelating compound advantageously is radiolabeled after attachment to the polymeric carrier to produce a radionuclide metal chelate of the formula:
• P represents the polymeric carrier
• M represents a radionuclide metal or oxide thereof, and the other symbols are as described above.
• Radionuclide metals include, but are not limited to, the diagnostically effective radionuclide 99m Tc, and the therapeutically effective radionuclides 188 Re, 186 Re, 67 Cu, 64 Cu, 212 Pb, 212 Bi, and 109 Pd. 186 Re and 188 Re are radionuclide metals for use in the present invention.
• the radiolabeling reaction (for this N 2 S 2 compound and the other chelating compounds described below) is conducted using conventional procedures.
• N 2 S 2 chelating compounds comprising carboxylic acid substituent (s) for improved biodistribution properties are described in copending U.S. Patent Application Serial number 07/367,502, entitled “Radionuclide Metal Chelates for the Radiolabeling of Proteins", which is hereby incorporated by reference.
• N 3 S chelating compound Another type of chelating compound that may be employed comprises one sulfur and three nitrogen donor atoms and thus may be designated an "N 3 S" chelating compound Suitable N 3 S chelating compounds include those described in European patent application publication number 284,071 and copending U.S. Patent Application Serial number 07/172,004, both entitled “Metal-Radionuclide-Labeled Proteins and Glycoproteins for Diagnosis and Therapy", which are hereby incorporated by reference in their entirety. Ex. .pies of N 3 S chelating compounds include but are not limited to the following seven compounds, wherein "T” represents a sulfur protecting group and "COOTFP" represents a 2,3,5,6-tetrafluorophenyl ester group:
• the COOTFP active ester may be replaced by other chemically reactive functional groups.
• chelating compounds may have different combinations of donor atoms.
• Such compounds include among others, the N 2 S 4 , N 2 S 3 , and N 3 S 3 chelating compounds described in copending U.S. Patent Application Serial no. 07/201,134, entitled “Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics", which is hereby incorporated by reference in its entirety.
• the chelating compounds comprise, or are attached to, cleavable linkers.
• linkers that are cleavable under defined conditions (e.g., at acidic pH, under reducing conditions, or in the presence of an enzyme such as a protease) are known.
• the chelates therefore may be released from the polymeric carrier under the desired conditions.
• Suitable chelating compounds comprising a cleavable link age include but are not limited to those described in copending U.S. Patent Application Serial no. 07/457,480, entitled "Radiolabeled Proteins for Diagnostic and
• N 2 S 2 and N 3 S chelating compounds comprising a linker of defined structure that terminates in a chemically reactive functional group.
• the linkage is cleavable at an ester group positioned in a particular orientation therein.
• Examples of such chelating compounds include, but are not limited to, the following:
• T represents a sulfur protecting group and Z represents a chemically reactive group (e.g., an active ester) which may be used to incorporate the chelating compound into the polymeric carrier in accordance with the present invention.
• Z represents a chemically reactive group (e.g., an active ester) which may be used to incorporate the chelating compound into the polymeric carrier in accordance with the present invention.
• molecules that bind radiohalogens at the meta or para position on a phenyl ring are described in U.S. Patent No. 4,855,153, entitled “Radiohalogenated Proteins", which is hereby incorporated by reference in its entirety. These compounds may be represented by the following formula:
• *X is a radioisotope of iodine, bromine, fluorine, or astatine
• Ar is an aromatic or heteroaromatic ring
• R is a chemical bond or a substituent containing 1 to 12 straight-chain carbon atoms that does not activate Ar toward electrophilic substitution on the order produced by hydroxy or amino substitution of the ring.
• the bond or substituent has attached thereto a chemically reactive functional group useful in the present invention for incorporation of the compound (or a non-radiolabeled precursor thereof) onto the polymeric carrier.
• *I-paraiodophenyl compounds in which *I represents a radioisotope of iodine
• n represents an integer from 0 to 3
• Z represents a reactive functional group
• *X represents a radioisotope of a halogen.
• radiohalogenated molecules that may be used in the present invention are described in U.S. Patent No. 4,876,081, which is hereby incorporated by reference in its entirety.
• the radiohalogenated molecules comprise a vinyl group.
• the radiolabeled polymeric carrier targeting molecules of the present invention have use in diagnostic and therapeutic procedures, both for in vitro assays and for in vivo medical procedures.
• the radiolabeled polymeric carrier molecules may be administered intravenously, intraperitoneally, intralymphatically, locally, or by other suitable means, depending on such factors as the type of target site.
• the amount to be administered will vary according to such factors as the type of radionuclide (e.g., whether it is a diagnostic or therapeutic radionuclide), the route of administration, the type of target site(s), the affinity of the targeting molecule for the target site of interest, and any cross-reactivity of the targeting molecule with normal tissues. Appropriate dosages may be established by conventional procedures and a physician skilled in the field to which this invention pertains will be able to determine a suitable dosage for a patient.
• a diagnostically effective dose is generally from about 5 to about 35 mCi and typically from about 10 to about 30 mCi per 70 kg body weight.
• a therapeutically effective dose is generally from about 20 mCi to about 300 mCi.
• conventional non-invasive procedures e.g., gamma cameras
• the target sites of interest e.g., tumors.
• an agent that raises urine pH may also be administered to the patient.
• agents include, for example, a salt of ascorbate (e.g., sodium ascorbate) or a bicarbonate salt (e.g., sodium bicarbonate), which may be administered intravenously.
• Raising the urine pH to a basic level promotes cleavage of the ester in conjugates or catabolites thereof localized in the kidneys. Clearance of the released radionuclide metal chelates from the body is thereby enhanced.
• Administration of such agents to promote cleavage of ester linkers in vivo is described in U.S. Patent Application Serial No. 07/251,900, which is hereby incorporated by reference.
• the comparatively low intestinal localization of the therapeutic radiolabeled polymeric carrier antibodies of the present invention or catabolites thereof permits increased dosages, since intestinal tissues are exposed to less radiation.
• the clarity and accuracy of diagnostic images also is improved by the reduced localization of radiolabeled polymeric carrier antibodies or catabolites thereof in normal tissues.
• peptide carriers containing 6, 12, and 18 ⁇ -amino acids with different side chain hydroxyl groups are synthesized to show the use of hydrazones in covalently linking to agents.
• the requisite peptides are synthesized using the solid phase methodology of Merrifield (G. Barany and R.B; Merrifield, "The Peptides. Analysis, Synthesis and Biology” E. Gross and J. Meinhofer, Editors, Academic Press, New York, pages 1-284 (1980).
• This example first involves the synthesis of peptide 1, N-Acetyl-L-seryl-L-aspartyl ( ⁇ -Otce)-L-seryl-L-threonyl- L-aspartyl-( ⁇ -Otce)-L-threronyl-7-aminobutyric acid. This is followed by the oxidation of the hydroxyl amino acid side chain groups to carbonyl groups. These carbonyl groups are then condensed with the hydrazide groups on the agents. Next, there is formation of the active ester on the C-terminal of the peptide. This enables the peptide or polymeric carrier with attached agents to conjugate with the antibody.
• Figure 1 illustrates a specific polymeric carrier synthesis and a specific conjugation procedure.
• the preferred protecting groups are Ser (0-benzyl), Thr (O-benzyl), Glu(O-t-butyl), Glu (0-benzyl), Asp(O-t-butyl) and Tyr(Br-Cbz) (G. Barany and R.B. Merrifield, "The Peptides. Analysis, Synthesis and Biology” E. Gross and J. Meinhofer, Editors, Academic Press, New York, pages 1-284 (1980)).
• the other preferred protecting group for glutamic and aspartic acids (and other carboxyl bearing side chains) is the trichloroethyl ester trichloroethoxycarbonyl for tyrosine (Tee).
• the presence of this protecting group on the carboxyl of Asp and Glu residues offer protection through the sequence of derivatization of the side chain, attachment of the agents and the final activation of the terminal carboxyl group for conjugation to the targeting molecule.
• the trichloroethyl group (s) can be removed by the using Zn-HOAc or Zn-THF-phosphate buffer (R.B. Woodward, K. Heusler, J. Gosteli, P. Naegeli, W. Oppolzer, R. Ramage, S. Ranganathan and H. Vorbruggen, J. Amer. Chem. Soc, 88, 852 (1989) and M.F. Sommelhack and G. E.
• cleavage of peptides from the resin are accomplished using the low-high HF cleavage procedure of Tam and Merrifield (J.P. Tam, W.F. Heath and R.B. Merrifield, "SN 2 deprotection of synthetic peptides with low concentration of HF in dimethyl sulfide: evidence and application in peptide synthesis.” J. Amer. Chem. Soc, 105, 6442 (1983)) (method A) or in 10:1:1:2 (by volume) of HF:anisole:dimethylsulfide:p-thiocresol for 1 hour at 5° to 0°C.
• the organic scavengers are extracted from the resin 3 times with ether and the peptides extracted twice with 5 mL volume of 20-40% HOAc/H 2 O.
• the peptides are purified on a semi-preparative Vydec LC4 reversed phase column using a gradient of 100% H 2 O-0.1% TFA to 40% H 2 O-0.1% TFA+60% CH 3 CN-0.1% TFA. They are analyzed for correct amino acid composition and molecular weight by FAB mass spectrometry ( T.D. Lee, "Methods of Protein Micro- characterization" J.E. Shively, editor. The Humana
• N-terminal Boc group is acetylated using labeled acetic anhydride.
• 10 mg of the peptide is N- acetylated with C-14-acetic anhydride (1 mCi, 11.3 mCi/mmol) which is added and shaken for 2.5 hours with the resin. A 5-fold molar excess of diisopropylethylamme was added and N-acetylation was continued for 30 minutes.
• Peptide resin sealed in 1 inch square polypropylene bags was washed several times with 4 mL/bag of methylene chloride, 5% diisopropylethylamme/ methylene chloride and finally with 10% cold acetic anhydride/methylene chloride to complete the a ⁇ etylation.
• Excess labelled anhydride was washed from the resin by consecutive rinses of methylene chloride, dimethyl formamide, isopropanol, methylene chloride, methanol and the resin was dried overnight prior to deblocking by the procedures described above.
• the N-terminal residue or all the residues are in the D-configuration.
• the change in the configuration of the peptide backbone will not alter the rate of the release of the therapeutic molecules attached to the side chain. However, this change may diminish the immunogenicity of the peptide backbone of these carriers.
• the next step involves Moffatt oxidation of peptide 1 to the corresponding carbonyl compound 2.
• the oxidation of the peptide is carried out using DMSO, DCC, pyridine trifluoroacetate, and benzene or toluene.
• Moffatt oxidation is preferred for compound 2 since the procedure does not result in over oxidation of the hydroxyl compound. (For general methods see, A.F. Cook and J.G. Moffatt, J. Amer. Chem. Soc, 89., 2697 (1967) and K. E. Pfitzner and J.G. Moffatt, J. Amer. Chem Soc, 87, 5661 (1965)).
• the next step is preparation (modification) of therapeutic molecules by changing their alcohol groups to hydrazides and then condensing them with modified peptides.
• the therapeutic molecules of interest are Verrucarin A and Roridin A which belong to the trichothecene group of antiboiotics (B.B. Jarvis and A. Acierto in "Trichothecene Mycotoxicosis: Pathyophysiological Effects” Vol. 1. V. R. Beasley, Editor, CRC Press, Boca Raton, FL, 1989. pp. 73-105).
• These compounds with broad spectrum biological activities are the most potent synthesis inhibitors containing C, H and 0. They exert their inhibition by interacting with the EF2 on the ribosomes (C.S.
• a similar strategy can be used to convert other molecules of therapeutic intrest containing alcohol function to hydrazide (after incorporating a succinyl moiety) for attachment to the defined polymer 2.
• molecules of therapeutic interest containing a carboxylic acid function can be attached to the defined polymer via the formation of a hydrazide.
• hydrazone 3 from compound 2 and Verrucarin A hydrazide 7.
• a solution of the peptide (l mmol) in isopropanol 5 mmol of Verrucarin A hydrazide (7; 10 mmol) is added and the solution is allowed to stand at room temperatures for several hours.
• the formation of hydrazone is followed chromatographically and is isolated either by crystallization or by C-18 column chromatography.
• the product is characterized by NMR and FAB mass spectrometry.
• the hydrazone derived from peptide 4 and Roridin A derivatives 9 and 10 are prepared in a similar manner.
• the next synthesis is the preparation of active ester 4 of peptide 3 (See Figure 3).
• To a solution of the peptide 3 in DMF, from the above reaction 3 equivalents of 2,3,5,6- tetrafluorophenol and 3 equivalents of DCC are added and the solution is stirred at room temperature for 10-12 hours.
• the precipitated dicyclohexylurea is removed by filtration and the residue is chromatographed to isolate the product.
• the product is dissolved in a phosphate buffer containing 10% tetrahydrofuran and the trichloroethyl groups are removed according to the procedure of M.F. Sommelhack and G.E. Heinsohn (J. Amer. Chem. Soc, 94 5139 (1972)) to yield the peptide or polymeric carrier 4, containing the therapeutic molecules and an active ester for attachment to the targeting
• the last step is the conjugation of the active ester 4 to the NR-LU-10 to give the conjugate 5.
• the active ester is condensed with NR-LU-10 murine monoclonal antibody, which recognizes a pancarcinoma antigen. Other proteins or fragments may be substituted for the NR-LU-10 antibody.
• NR-LU-10 murine monoclonal antibody which recognizes a pancarcinoma antigen.
• Other proteins or fragments may be substituted for the NR-LU-10 antibody.
• a solution of the antibody at pH 9-9.5 a solution of the active ester in 250 mM bicarbonate buffer at pH 9.3 is added and gently agitated to mix and incubated at room temperature for 30 minutes to allow conjugation of the peptide carrier to the antibody.
• the conjugate is purified in a column containing an anion exchanger DEAE- sephadex or QAE-sephadex. All of the above reactions are shown in Figure 2.
• conjugates are prepared from longer chain peptides, N-Acetyl-[L-seryl-L-aspartyl( ⁇ -Otce)-L- seryl-L-threonyl-L-aspartyl-( ⁇ -Otce)-L-threonyl] 2 - ⁇ - aminobutyric acid, peptide 11 and N-Acetyl-L-seryl-L- aspartyl ( ⁇ -Otce)-L-seryl-L-threonyl-L-aspartyl ⁇ -Otce) L- threonyl- ⁇ -aminobutyric acid, peptide 12.
• This example covers the attachment of bifunctional chelate ligands to the defined peptide or polymeric conjugation of the carrier to the antibody followed by radiolabeling .
• N-Acetyl-L-tyrosyl (O-CO-CH 2 -CCl 3 ) - L-Asp ( ⁇ -OtBu)-Glu(7-OtBu)-Gly-Glu(7-OtBu)-7-Aba-PAMresin 16
• the protecting group in each step is 9- flourenylmethoxycarbonyl (Fmoc) rather than the N-tBoc group used in the synthesis of 1.
• 10 mg of the peptide is N- acetylated with C-14 acetic anhydride (1 mCi, 11.3 mCi/mmol) which is added and shaken for 2.5 hours with the resin. A 5-fold molar excess of diisopropylethylamme is added and N-acetylation was continued for 30 minutes. Peptide resin sealed in 1 inch square polypropylene bags was washed several times with 4 mL/bag of methylene chloride, 5% diisopropylethylamine/methylene chloride and finally with 10% cold acetic anhydride/methylene chloride to complete the acetylation.
• the N-terminal residue or all the residues are in the D-configuration.
• the change in the configuration of the peptide back bone will not alter the rate of the release of the therapeutic molecules attached to the side chain. This change may also diminish the immunogenicity of the peptide backbone of these carriers.
• the synthesis of S-ethoxyethylmercaptoacetyl- glycylglycylserinetrichloroethyl ester 24 involves first the synthesis of N-t-Boc-Serine-O-benzyl- trichloroethyl ester 18. To a solution of N-t-Boc- serine-O-benzyl ether (5 mmol) in methylene chloride containing 5 mmol of triethylamine, 5 mmol of N, N-dicyclohexylcarbodiimide was added and the solution was stirred at room temperature overnight.
• the precipitated dicyclohexylurea was filtered and the filtrate was washed with 1% HCl and water.
• the organic layer was dried over anhydrous Na 2 SO 4 , and evaporated to give the trichloroethyl ester, which was purified over a silica gel column.
• Serine trichloroethyl ester trifluoroacetate 19 is prepared in the following manner. A solution of 4 mmol of the above compound 18, in 50 mL of glacial acetic acid containing 200 mg of palladium on charcoal was hydrogenated at 60 psi in a Paar apparatus for 10-12 hours. The catalyst was removed by filtration over celite and the solvent was removed in vacuo to give N-t-Boc serine trichloroethyl ester, an oil, which was dried overnight and used without further purification. The oil was stirred with 10 mL 50% trifluoroacetic acid-CH 2 Cl 2 for 3 hours at room temperature to remove the Boc group.
• S-(l-ethoxylethyl) mercaptoacetic acid 20 is prepared according to the following. A solution of mercaptoacetic acid (17.4 mL, 250 mmol) in 125 mL of dichloromethane containing p-toluenesulfonic acid monohydrate (0.24 g, 1.26 mmol) was cooled to -18 to -25°C with stirring.
• the organic scavengers are extracted from the resin 3 times with ether and the peptides extracted twice with 5 mL volume of 20-40% HOAc/H 2 O.
• the peptides are purified on a semi-preparative Vydec LC4 reversed phase column using a gradient of 100% H 2 O-0.1% TFA to 40% H 2 O-0.1% TFA+60% CH 3 CN-0.1% TFA. They are analyzed for correct amino acid composition and molecular weight by FAB mass spectrometry (Ref: T.D. Lee, "Methods of Protein Microcharacterization" J.E. Shively, editor. The Humana Press, Clifton, New Jersey, p. 403 (1986)).
• the product 27 is dissolved in a phosphate buffer containing 10% tetrahydrofuran and the trichloroethyl groups are removed according to the procedure of M. F. Sommelhack and G.E. Heinsohn (J. Amer. Chem Soc, 94, 5139 filtration and the residue is chromatographed to isolate the product, 27.
• the product 27 is dissolved in a phosphate buffer containing 10% tetrahydrofuran and the trichloroethyl groups are removed according to the procedure of M. F. Sommelhack and G.E. H ⁇ insohn (J. Amer. Chem Soc, 94, 5139 (197Z)) to yield the peptide carrier 28, containing the chelator capable of forming metabolically stable complexes with radionuclides and an active ester for attachment to the targeting molecule.
• the peptide containing the chelator radiolabeled with 186 Re according to the following procedure.
• Sodium perrhenate produced from a W/Re generator is combined with citric acid (a preferred complexing agent for 186 Re) , a reducing agent (usually SnCl 2 ).
• the resulting 186 Re -citrate exchange complex is heated with the chelating compound 28 at 75°-100°C for 10-15 minutes and then transferred to a 0°C ice bath for a few minutes to obtain the peptide 29 containing 186 Re-complexes on the side chain.
• the antibody (whole or fragments) is added and incubated at room temperature for 10-15 minutes to complete the conjugation to the antibody.
• the conjugate so produced is purified using an anion exchange column

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Genetics & Genomics (AREA)
• Optics & Photonics (AREA)
• Physics & Mathematics (AREA)
• Immunology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Applications Claiming Priority (5)

Publications (3)

Family

ID=27080742

Family Applications (1)

Country Status (6)

Families Citing this family (31)

Citations (5)

Family Cites Families (15)

• 1991
  • 1991-09-27 AU AU87306/91A patent/AU8730691A/en not_active Abandoned
  • 1991-09-27 AT AT91918218T patent/ATE152917T1/de not_active IP Right Cessation
  • 1991-09-27 WO PCT/US1991/007143 patent/WO1992005802A1/en active IP Right Grant
  • 1991-09-27 EP EP91918218A patent/EP0510132B1/de not_active Expired - Lifetime
  • 1991-09-27 DE DE69126124T patent/DE69126124T2/de not_active Expired - Fee Related
• 1993
  • 1993-06-03 US US08/071,357 patent/US5549883A/en not_active Expired - Fee Related

Patent Citations (5)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events